Prostatic Soy Isoflavone Concentrations Exceed Serum Levels After Dietary Supplementation

Overview

Journal Prostate

Date 2009 Jan 31

PMID 19180569

Citations 27

Authors

Christopher D Gardner

Beibei Oelrich

Jenny P Liu

David Feldman

Adrian A Franke

James D Brooks

Affiliations

Soon will be listed here.

Abstract

Background: The effects of soy isoflavones on prostate cancer may be concentration-dependent. The impact of soy supplementation on isoflavone concentrations in prostate tissues and serum remain unclear.

Objective: To assess and compare concentrations of soy isoflavones in prostate tissue and serum among 19 men with prostate cancer who had elected to undergo radical prostatectomy.

Methods: Participants were randomized to receive either daily soy supplements (82 mg/day aglycone equivalents) or placebos for 2 weeks (14 days) prior to surgery. Serum samples were obtained at the time of the surgery. Isoflavone concentrations were measured by HPLC/ESI-MS-MS.

Results: The median (25th, 75th percentile) total isoflavone concentration in the isoflavone-supplemented group was 2.3 micromol/L (1.2, 6.9) in the prostate tissue and 0.7 micromol/L (0.2, 1.2) in the serum. Total isoflavone concentrations in this group were an average of approximately 6-fold higher in prostate tissue compared to serum; the tissue versus serum ratio was significantly lower for genistein than daidzein, 4-fold versus 10-fold, P = 0.003. Tissue and serum levels of isoflavones among the placebo group were negligible with a few exceptions.

Conclusions: The findings from the present study suggest that prostate tissue may have the ability to concentrate dietary soy isoflavones to potentially anti-carcinogenic levels.

Citing Articles

The effects of soymilk plus probiotics supplementation on cardiovascular risk factors in patients with type 2 diabetes mellitus: a randomized clinical trial.

Hasanpour A, Babajafari S, Mazloomi S, Shams M BMC Endocr Disord. 2023; 23(1):36.

PMID: 36759798 PMC: 9912676. DOI: 10.1186/s12902-023-01290-w.

Inhibition of α-Adrenergic, Non-Adrenergic and Neurogenic Human Prostate Smooth Muscle Contraction and of Stromal Cell Growth by the Isoflavones Genistein and Daidzein.

Huang R, Liu Y, Hu S, Tamalunas A, Waidelich R, Strittmatter F Nutrients. 2022; 14(23).

PMID: 36500973 PMC: 9735664. DOI: 10.3390/nu14234943.

Essential Elements and Isoflavonoids in the Prevention of Prostate Cancer.

Stanislawska I, Figat R, Kiss A, Bobrowska-Korczak B Nutrients. 2022; 14(6).

PMID: 35334882 PMC: 8949525. DOI: 10.3390/nu14061225.

Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health Benefits.

Sharifi-Rad J, Quispe C, Imran M, Rauf A, Nadeem M, Gondal T Oxid Med Cell Longev. 2021; 2021:3268136.

PMID: 34336089 PMC: 8315847. DOI: 10.1155/2021/3268136.

Randomized, Placebo-Controlled Six-Month Intervention Study of Soy Protein Isolate in Men with Biochemical Recurrence after Radical Prostatectomy: A Pilot Study.

Bosland M, Schmoll J, Watanabe H, Randolph C, Kato I Nutr Cancer. 2021; 74(2):555-564.

PMID: 33764851 PMC: 8756455. DOI: 10.1080/01635581.2021.1903949.

References

Rannikko A, Petas A, Rannikko S, Adlercreutz H . Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestogen supplementation. Prostate. 2005; 66(1):82-7. DOI: 10.1002/pros.20315. View

Hong S, Kim S, Kwon S, Lee J, Chung B . Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hyperplasia. Yonsei Med J. 2002; 43(2):236-41. DOI: 10.3349/ymj.2002.43.2.236. View

Williamson G, Manach C . Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr. 2005; 81(1 Suppl):243S-255S. DOI: 10.1093/ajcn/81.1.243S. View

Davis J, Kucuk O, Sarkar F . Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells. Mol Carcinog. 2002; 34(2):91-101. DOI: 10.1002/mc.10053. View

Manach C, Williamson G, Morand C, Scalbert A, Remesy C . Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr. 2005; 81(1 Suppl):230S-242S. DOI: 10.1093/ajcn/81.1.230S. View

Farhan H, Wahala K, Adlercreutz H, Cross H . Isoflavonoids inhibit catabolism of vitamin D in prostate cancer cells. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 777(1-2):261-8. DOI: 10.1016/s1570-0232(02)00081-8. View

Heald C, Ritchie M, Bolton-Smith C, Morton M, Alexander F . Phyto-oestrogens and risk of prostate cancer in Scottish men. Br J Nutr. 2007; 98(2):388-96. DOI: 10.1017/S0007114507700703. View

Majid S, Kikuno N, Nelles J, Noonan E, Tanaka Y, Kawamoto K . Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res. 2008; 68(8):2736-44. DOI: 10.1158/0008-5472.CAN-07-2290. View

Kang N, Lee K, Rogozin E, Cho Y, Heo Y, Bode A . Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. J Biol Chem. 2007; 282(45):32856-66. DOI: 10.1074/jbc.M701459200. View

10.

Joniau S, Goeman L, Roskams T, Lerut E, Oyen R, van Poppel H . Effect of nutritional supplement challenge in patients with isolated high-grade prostatic intraepithelial neoplasia. Urology. 2007; 69(6):1102-6. DOI: 10.1016/j.urology.2007.02.063. View

11.

Lazarevic B, Karlsen S, Saatcioglu F . Genistein differentially modulates androgen-responsive gene expression and activates JNK in LNCaP cells. Oncol Rep. 2008; 19(5):1231-5. View

12.

Morton M, Chan P, Cheng C, Blacklock N, Correia R, Lloyd S . Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong, and the United Kingdom. Prostate. 1997; 32(2):122-8. DOI: 10.1002/(sici)1097-0045(19970701)32:2<122::aid-pros7>3.0.co;2-o. View

13.

Swami S, Krishnan A, Moreno J, Bhattacharyya R, Peehl D, Feldman D . Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J Nutr. 2006; 137(1 Suppl):205S-210S. DOI: 10.1093/jn/137.1.205S. View

14.

Davis J, Kucuk O, Sarkar F . Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer. 2000; 35(2):167-74. DOI: 10.1207/S15327914NC352_11. View

15.

Watanabe S, Yamaguchi M, Sobue T, Takahashi T, Miura T, Arai Y . Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J Nutr. 1998; 128(10):1710-5. DOI: 10.1093/jn/128.10.1710. View

16.

Hedlund T, Maroni P, Ferucci P, Dayton R, Barnes S, Jones K . Long-term dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in caucasian men. J Nutr. 2005; 135(6):1400-6. DOI: 10.1093/jn/135.6.1400. View

17.

Yan L, Spitznagel E . Meta-analysis of soy food and risk of prostate cancer in men. Int J Cancer. 2005; 117(4):667-9. DOI: 10.1002/ijc.21266. View

18.

Lo F, Mak N, Leung K . Studies on the anti-tumor activities of the soy isoflavone daidzein on murine neuroblastoma cells. Biomed Pharmacother. 2007; 61(9):591-5. DOI: 10.1016/j.biopha.2007.08.021. View

19.

Vaishampayan U, Hussain M, Banerjee M, Seren S, Sarkar F, Fontana J . Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer. 2007; 59(1):1-7. DOI: 10.1080/01635580701413934. View

20.

Bosland M, Gann P . Soy isoflavone consumption is not associated with increased risk of advanced prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(10):2169. DOI: 10.1158/1055-9965.EPI-07-0414. View